Alayne D. Markland, DO, MSc
University of Alabama at Birmingham
Birmingham VA Medical Center
Manju Taneja Beier, PharmD, BSPharm
President, Geriatric Consultant Resources LLC
Adjunct Clinical Associate Professor
College of Pharmacy
The University of Michigan
Ann Arbor, MI
Pharmacists: 0.75 Contact Hour (0.075 CEU)
Overactive bladder (OAB) is the most common cause of urinary incontinence or loss of bladder control in adults and affects approximately 33 million Americans – nearly 2 in 10 adults and a full 30% of the senior population. The medical issue of OAB is of particular importance in the older adult population with prevalence greatly increasing in older adults. The symptoms of OAB — urge urinary incontinence (UI), urgency, and urinary frequency — often lead to further medical and psychological problems and can have a devastating impact on quality of life.
Yet according to the National Committee for Quality Assurance (NCQA), only 35.5% of patients over age 65 who have experienced a problem with urine leakage have received treatment for this problem. The reasons for this are numerous. Through this activity, senior care pharmacists and other senior care clinicians can address these issues which include poor patient adherence, drug-drug interactions, and clinician challenges in understanding the differences in available pharmacologic therapies.
Senior care pharmacists and clinicians have an opportunity to provide optimal management for older adults experiencing OAB, ultimately improving outcomes for the many older adults who suffer from it.
. Target Audience
Senior care pharmacists and others interested in the care of older patients with OAB.
Upon completion of this educational activity, the participant should be able to:
Develop effective treatment plans for older adults with overactive bladder.
Evaluate the efficacy and safety of current and emerging therapies for adults with overactive bladder.
Address the current long term care regulations for the evaluation and management of urinary incontinence.
Minimize medication side effects in treatment plans for older adults with overactive bladder.
It is the policy of the ASCP to ensure balance, independence, objectivity and scientific rigor in all of its educational activities including those which are sponsored and cosponsored. All faculty are expected to disclose any significant financial interest or other relationship with the manufacturer(s) of any commercial product(s) and/or provider(s) of commercial services discussed in an educational presentation. The intent of this disclosure is not to prevent a presenter with significant financial interest or other relationship from making the presentation, but rather to provide the audience with information with which they can make their own judgments. It remains for the audience to determine whether the speaker's interests or relationships may influence the presentation with regard to exposition or conclusion. Faculty are also expected to openly disclose any off-label, experimental, or investigational use of drugs or devices in their presentations.
Dr. Markland has no relevant financial conflicts to disclose.
Dr. Beier has no relevant financial conflicts to disclose.
Dr. Joseph Kim has no relevant financial conflicts to disclose.
Dr. Agnes Yang has no relevant financial conflicts to disclose.
This educational activity may contain discussion of published and/or investigational uses of pharmaceutical agents. Some uses of these agents may not have been approved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings. Credit Statements
The American Society of Consultant Pharmacists (ASCP) is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This knowledge-based activity, ACPE Universal Activity #0203-9999-12-019-H01-P, has been assigned 0.75 Contact Hour (0.075 CEU).
Participants must view the activity in its entirety, successfully complete the post-test, and submit an evaluation to receive continuing pharmacy education credit. Credit will be awarded for a score of 75% or better, and a statement may be printed immediately after passing the post-test.
There is no fee to participate in this educational activity.
Commercial Support Statements
This activity is supported by an independent educational grant from Pfizer Inc.
This activity is supported by an independent educational grant from Astellas Pharma Global Development, Inc.
Minimum System Requirements:
• Pentium III, 600 MHz or Equivalent Processor
• 512 MB of RAM
• Windows XP, Vista, or 7
• Mac OS X
• 800x600 Monitor Resolution
• 16-bit Color
• 16 bit Sound Card with Speakers
Please turn off all pop-up blockers to assure access to the educational activity.
Click on the "Start program" icon at the bottom of this page. If you are not already registered as a user of this website, this will bring you to the login/registration page where you will be able to register as a new CMEcorner.com member or check existing registration information. When ready, click on the "Continue to Program" icon at the bottom of the screen.
The next screen will permit you to check for or download the Flash player required to run this program and to begin the program presentation. The activity will take approximately 45 minutes to complete.
After the activity has finished, click on the "Post-test" button.
Instructions for completing and submitting the post-test and evaluation are provided on the post-test screen.
© 2012, Medical Communications Media, Inc. All rights reserved. None of the contents may be reproduced in any form without prior written permission from the publisher. The opinions expressed in this educational activity are those of the faculty and do not necessarily reflect the opinions or recommendations of their affiliated institutions, the publisher, and ASCP. Any medications, diagnostic procedures, or treatments discussed by the faculty should not be used by clinicians or other health care professionals without first evaluating their patients’ conditions, considering possible contraindications or risks, reviewing any applicable manufacturer’s product information, and comparing any therapeutic approach with the recommendations of other authorities.